A radiotherapy regime involving higher doses of radiation is a better option than having lower doses for men with localised prostate cancer, according to a new report.
The 10-year results of the largest trial of its kind published in The Lancet Oncology show 37 rounds, or fractions, of radiotherapy at 74 Gray (Gy) – compared with 32 fractions at 64 Gy – controlled the disease more effectively. This also reduced the chance that men would need follow-up hormone-deprivation therapy, which can have long-term side-effects.
The findings come from the major RT01 phase III trial. The trial was led by Professor Dearnaley at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and was funded and conducted by the Medical Research Council Clinical Trials Unit at UCL. The study also involved several leading clinical research centres in the UK, New Zealand and Australia.
In addition, the study demonstrated the overall effectiveness of radiotherapy for men with localised disease. Almost three quarters of men treated with either the more or less intensive radiotherapy regimes were still alive after 10 years.Further reading: Keeping active improves prostate cancer prognosis, report says
Set up in 1998, the trial split 843 men with localised prostate cancer into two groups to compare the two doses of radiotherapy. Some 421 men had the less and 422 the more intensive treatment regimes. Both groups also had standard hormone-deprivation treatment alongside their radiotherapy.
The five-year results of the trial have previously shown the benefits of dose-escalated radiotherapy, and played an influential role in changing NICE guidance to recommend it in prostate cancer. Dose escalation is now the norm for localised prostate cancer in the UK.
The new 10-year results further strengthen the evidence for choosing dose-escalation radiotherapy, as well as showing the long-term benefits of the treatment.
After 10 years, 55 per cent of men on the 37-fraction regime, compared with 43 per cent of men on the 32-fraction regime, had survived without their disease progressing into a more hazardous form, as measured by the standard prostate-specific antigen (PSA) test. In each half of the study, 71 per cent of men were alive after 10 years and only 11 per cent had died from prostate cancer.
Men who received the higher dose were more likely to have side-effects associated with radiotherapy, but few men had severe side-effects. Receiving the higher dose reduced the need for follow-up hormone treatment, which also carries a risk of side-effects.
The trial did not show that men given dose-escalated radiotherapy live longer, but both groups of men lived much longer than expected. Almost three quarters of all the men in the study were still alive after 10 years, and of the 236 men who had died since treatment, only 91 had died of prostate cancer.
Study leader Professor David Dearnaley, Professor of Uro-Oncology at The Institute of Cancer Research, London, and Honorary Consultant at the Royal Marsden NHS Foundation Trust, said: “Our study has proved that treating men with localised prostate cancer using higher doses of radiotherapy is more effective than a less intensive regime. The dose-escalated regime is safe in the long term, and reduces the chances that a cancer will return and men will require further hormone-deprivation treatment. The side-effects of hormone treatment do need to be balanced against those of the extra radiotherapy doses, but overall our study has shown men are better off after having the escalated regime, as is now the norm in the UK.
“Another key finding to come out of our study is that radiotherapy in general is both a safe and an effective treatment for localised prostate cancer. Almost three quarters of men treated with either the more or less intensive radiotherapy regimes are still alive after 10 years, and of the men who have died, less than half actually died from prostate cancer.
“Further refinements in radiotherapy techniques since our trial began have made treatment even safer and are very important as men with localised prostate cancer have such favourable long-term survival prospects.”
Matthew Sydes, Senior Scientist and Statistician at the MRC Clinical Trials Unit at UCL, said: “The RT01 trial has already changed how men with localised prostate cancer are treated. The current NICE guidelines recommend the use of the higher dose of radiotherapy, based on the five-year results of RT01. The trial also helped to develop guidelines on how to limit the radiation that organs near the tumour receive, and helped hospitals across the UK to introduce quality-assured conformal radiotherapy. It is now contributing to biological studies to help better understand the disease and the side-effects of radiotherapy.”